0001950047-26-004130.txt : 20260506
0001950047-26-004130.hdr.sgml : 20260506
20260506162533
ACCESSION NUMBER: 0001950047-26-004130
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20260506
DATE AS OF CHANGE: 20260506
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Apogee Therapeutics, Inc.
CENTRAL INDEX KEY: 0001974640
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
EIN: 934958665
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-41740
FILM NUMBER: 26948891
BUSINESS ADDRESS:
STREET 1: 221 CRESCENT ST.
STREET 2: BUILDING 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 650-394-5230
MAIL ADDRESS:
STREET 1: 221 CRESCENT ST.
STREET 2: BUILDING 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
FORMER COMPANY:
FORMER CONFORMED NAME: Apogee Therapeutics, LLC
DATE OF NAME CHANGE: 20230420
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dambkowski Carl
CENTRAL INDEX KEY: 0001983476
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 144
MAIL ADDRESS:
STREET 1: 221 CRESCENT ST.
STREET 2: BUILDING 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
144
1
primary_doc.xml
144
0001983476
XXXXXXXX
LIVE
0001974640
Apogee Therapeutics, Inc.
001-41740
221 Crescent St., Building 17 Suite 102b
Waltham
MA
02453
6503945230
CARL DAMBKOWSKI
Officer
Common
Morgan Stanley Smith Barney LLC Executive Financial Services
1 New York Plaza
8th Floor
New York
NY
10004
22000
1832380.00
69485247
05/06/2026
NASDAQ
Common
05/06/2026
Exercise of Stock Options
Issuer
N
16500
05/06/2026
Cash
Common
12/14/2022
Restricted Stock Awards
Issuer
N
5500
12/14/2022
N/A
N
10b5-1 Sales for CARL DAMBKOWSKI
221 Crescent St., Building 17 Suite 102b
Waltham
MA
02453
Common
04/01/2026
5500
466639.80
10b5-1 Sales for CARL DAMBKOWSKI
221 Crescent St., Building 17 Suite 102b
Waltham
MA
02453
Common
03/04/2026
5500
390839.05
The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
05/06/2026
09/22/2025
/s/ Carl Dambkowski